

Osphena® (ospemifene) – New indication

- On January 29, 2019, <u>Duchesnay announced</u> the FDA approval of <u>Osphena (ospemifene)</u>, for the
 treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy (VVA),
 due to menopause.
 - Osphena is also approved for the treatment of moderate to severe dyspareunia, a symptom of VVA, due to menopause.
- Vaginal dryness is one of the two most common and most bothersome symptoms (MBS) of VVA due to menopause.
- The new indication for Osphena was based on three studies that evaluated vaginal dryness. Patients were treated with Osphena or placebo for 12 weeks.
 - In study 2, a statistically significant improvement in the moderate to severe MBS of vaginal dryness was not demonstrated.
 - In study 1, the least squares mean change from baseline in the moderate to severe MBS of vaginal dryness was -1.3 for the Osphena group (N = 113) vs. -0.9 for the placebo group (N = 104); p = 0.0136.
 - In study 3, the mean change from baseline in the moderate to severe MBS of vaginal dryness was -1.3 for the Osphena group (N = 269) vs. -0.9 for the placebo group (N = 263); p < 0.0001.
- Osphena carries a boxed warning for endometrial cancer and cardiovascular disorders.
- The recommended dosage of Osphena for either indication is one 60 mg tablet with food once daily.
 - Use of Osphena should be for the shortest duration consistent with treatment goals and risks for the individual woman.
 - Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.